Le Lézard
Classified in: Health
Subject: PDT

BIOLASE ANNOUNCES SUPPORT FOR PROJECT HOME


LAKE FOREST, Calif., June 27, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has partnered with Project HOME, an organization that provides dental services to patients from their first birthday to adulthood. Project HOME's Healthcare Services is a Federally Qualified Health Center (FQHC) and supports health care services, regardless of a person's ability to pay for the services, in Philadelphia.    

The mission of Project HOME is to empower adults, children, and families to break the cycle of homelessness and poverty, alleviate the underlying causes of poverty, and enable individuals to attain their fullest potential as individuals and as members of the broader society. Project HOME strives to create a safe and respectful environment to support individuals struggling with self-esteem, recovery, confidence, as well as mental and physical health.

Project HOME's dental services are part of a patient-centered, integrated health care service model, where many dental patients are also primary care patients. This allows medical issues that may impact oral health to be identified early and for treatment to begin to improve the patients' overall well-being.

During a ride-along with the BIOLASE team in Philadelphia, BIOLASE's President and Chief Executive Officer, John Beaver, was invited to visit Project HOME to see how the company could assist people in need. "At BIOLASE, our goal is to develop dental laser technology that provides a higher standard of care to the patient and improves patients' oral health," said Beaver. "Supporting Project HOME in their mission gives BIOLASE an opportunity to make a meaningful contribution to the overall health of the community."

"It is a great honor that BIOLASE has partnered with Project HOME to help provide dental care to our members. With the donation of an iPlus Waterlase laser system and the training program offered to our doctors and staff at Project HOME's dental facility in Philadelphia, the modern technology offered by BIOLASE will help provide a new standard of care for Project HOME members," commented Dr. Janine Burkhardt, Project HOME's Dental Director. "Improving the already excellent care each member receives, while assisting the doctors to complete more treatments in one visit, will have a significant impact on our ability to achieve our mission and improve our members' oral health outcomes."

About Project HOME

Since 1989, Project HOME has helped thousands of people break the cycle of homelessness and poverty by providing a continuum of care that includes street outreach, supportive housing and comprehensive services that focus on health care, education and employment through both adult and youth education and enrichment programs. To learn more, visit www.projecthome.org.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Expresstm, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements regarding the anticipated roll out of new go-to-market sales strategies, the Company's efforts to achieve its goal of becoming EBITDA positive. Forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," "should," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described, from time-to-time, in the "Risk Factors" section of BIOLASE's annual reports filed on Form 10-K with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

For further information, please contact:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
[email protected] / [email protected]

SOURCE BIOLASE, Inc.


These press releases may also interest you

at 05:10
Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions. These devices could be anything from equipment that helps stimulate the nervous system to...

at 05:04
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited...

at 04:28
GymNation, the homegrown UAE fitness brand, has today announced that due to unprecedented growth, it is reaching capacity across its 12 UAE gym locations and diversifying into a new market, brewing up a storm with the launch of its first-ever branded...

at 04:00
Cancer spreads from its primary tumor to other parts of the body via blood or the lymphatic system in a process termed 'metastasis'. This usually represents an advanced stage in the disease's progression and tends to be fatal. Therefore, preventing...

at 03:30
Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting...

at 03:13
Orexo's Annual and Sustainability Report for 2023 has been published and can be downloaded at, www.orexo.com. The Swedish version of the Report is also available on the company's website in European Single Electronic Format (ESEF). A PDF version is...



News published on and distributed by: